Skip to main content
. 2021 Sep 3;11(9):e047344. doi: 10.1136/bmjopen-2020-047344

Figure 5.

Figure 5

Meta-analyses of omalizumab versus placebo, comparing efficacy and safety. Outcomes assessed are: (A) serious adverse events (SAEs), (B) adverse events (AEs), (C) rescue systemic corticosteroid (RSCS) and (D) reduced need for surgery (RNS). M-H, Mantel-Haenszel.